Project Grant K00EY036684
- This $695,018 federal project grant awarded by the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) supports research to define how Müller glia (MG) cells, which function as injury-responsive stem cells, can enable retinal regeneration in zebrafish, mice, and potentially humans. The research aims to identify genes that regulate the regenerative potential of MG cells in the context of selective retinal cell loss, as occurs in degenerative eye diseases. By conducting...
- This Project Grant award from the National Eye Institute (CFDA 93.867 Vision Research) provides $393,008.00 to the University of California, Davis to conduct research on axonal regeneration in the frog Xenopus laevis. The goal is to systematically understand how this species successfully recovers from optic nerve injuries and regains vision, with the potential to translate these findings into therapies. Key activities include live imaging-based experiments to investigate the roles of the DLK and...
- This Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) to The Trustees of the University of Pennsylvania, doing business as Clinical Practices of the University of Pennsylvania, provides $590,160.00 in funding to characterize photoreceptor precursor cells for retinal transplantation. The research aims to improve understanding of photoreceptor development and investigate avenues for photoreceptor regeneration to restore vision, as retinal degenerative diseases...
- The National Eye Institute (NEI) awarded a $249,000 project grant to the Trustees of Indiana University, doing business as Indiana University, to investigate the recovery of retinal function following gene therapy for inherited retinal degenerations. The project, titled "The Contribution of Plasticity to the Recovery of Retinal Function Following Gene Therapy," aims to elucidate the fundamental mechanisms that enable the retina to establish functional connections after gene therapy....
- This federal Project Grant award from the National Eye Institute (NEI), under the CFDA program "Vision Research", provides $132,597 to The Schepens Eye Research Institute, Inc. to investigate the role of neural activity in retinal ganglion cell (RGC) integration and functional connectivity to improve RGC replacement therapies for glaucoma. The research aims to 1) characterize retinal remodeling following RGC inactivation, and 2) determine if inhibiting host neural activity can...
- This federal Project Grant award from the National Eye Institute (NEI), under the Vision Research program (CFDA 93.867), provides $427,625 to the University of Wisconsin-Madison to conduct research on defining folate-dependent single-cell methylomic and transcriptomic networks in distinct retinal ganglion cell (RGC) types associated with axon regeneration. The research aims to isolate and analyze regenerating versus non-regenerating RGCs to identify molecular profiles that distinguish RGC...
- This Project Grant award from the National Eye Institute (NEI), part of the U.S. Department of Health and Human Services, under the Vision Research (CFDA 93.867) program, provides $500,500 to support research on the role of retinal ganglion cells in shaping the identity and function of neurons in the superior colliculus visual processing region. The key objectives are to: 1) determine how retinal input influences the morphology and transcriptional profiles of genetically-defined neuron...
- This $146,922 project grant award from the National Eye Institute's Vision Research program (CFDA 93.867) supports research at The Johns Hopkins University to understand the chromatin architectural landscape of retinal development at the single-cell level. The project aims to identify how transcription factors manipulate genomic structure to control cell fate specification in the retina, a model system for studying neuronal development. Specifically, the research will use single-cell Hi-C and...
- This Project Grant award from the National Eye Institute's Vision Research program (CFDA 93.867) is supporting research at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to investigate the role of neuronal activity on retinal angiogenesis and blood-retina barrier (BRB) maturation. The $248,999 award, effective from May 1, 2025 to April 30, 2028, aims to elucidate how neuronal synaptic activity, specifically cholinergic and glutamatergic neurotransmitters,...
- The National Eye Institute, through its Vision Research program (CFDA 93.867), awarded a $464,750 project grant to President and Fellows of Harvard College, doing business as Harvard Medical School, to support research aimed at understanding how cell lineage contributes to the development of cell diversity in different regions of the chicken retina, including the high acuity area. The project will utilize a new lineage tracing tool called SCRIBBLE to reconstruct lineage "trees" and...
ELUCIDATING THE GENE REGULATORY NETWORKS THAT DRIVE NEURAL REGENERATION - PROJECT SUMMARY / ABSTRACT THERE ARE NO EFFECTIVE TREATMENTS TO REPLACE DAMAGED RETINAL NEURONS, REFLECTING A FUNDAMENTAL INABILITY FOR HUMANS TO MOUNT ROBUST REGENERATIVE RESPONSES WITHIN THE CENTRAL NERVOUS SYSTEM. TO ADDRESS THIS, IT WILL BE CRITICAL TO UNDERSTAND THE DIVERSITY OF GENE REGULATORY MECHANISMS THAT CAN IMPEDE OR DRIVE NEURON REGENERATION ACROSS VERTEBRATE CONTEXTS. EMBRYONIC AMNIOTES HAVE A TRANSITORY ABILITY TO REGENERATE RETINAL NEURONS FROM CELLS OF THE RETINAL PIGMENT EPITHELIUM (RPE) IF SUPPLIED WITH EXOGENOUS FGF2 AT THE TIME OF RETINAL INJURY. THIS MECHANISM OF REGENERATION CAN BE READILY INDUCED AT EMBRYONIC DAY 4 (E4) OF CHICKEN DEVELOPMENT, BUT RPE NEURAL COMPETENCE IS LOST BY EMBRYONIC DAY 5 (E5). THE OVERARCHING OBJECTIVE OF THE PROPOSED RESEARCH IS TO PROFILE CHANGES IN GENE REGULATION THAT DISPOSSESS RPE CELLS OF THEIR NEURAL COMPETENCY AS THEY DIFFERENTIATE. SPECIFIC AIM 1 WILL INTERROGATE TRANSCRIPTION FACTOR REGULATORY ACTIVITY WITHIN RPE CELLS ACROSS THE E4 / E5 DEVELOPMENTAL WINDOW BY INTEGRATING GENE EXPRESSION ANALYSIS, CHROMATIN ACCESSIBILITY PROFILING, AND TRANSCRIPTION FACTOR BINDING ASSAYS. PRELIMINARY BULK AND SINGLE NUCLEI RNA-SEQ DATASETS REVEALED THE ACUTE ACTIVATION OF NEURAL RETINA TRANSCRIPTION FACTOR PROFILES AT BOTH E4 AND E5, SUCH AS PAX6, ASCL1, AND VSX2. IN CONTRAST, GENES ASSOCIATED WITH RPE MATURITY, SUCH AS OTX2 AND PIGMENTATION GENES, WERE ELEVATED IN THE E5 RPE INDEPENDENTLY OF RETINECTOMY AND FGF2 TREATMENT. SIMILARLY, CHROMATIN ACCESSIBILITY SUGGESTED WIDER DYSREGULATION OF OTX2 AND RELATED HOMEOBOX TRANSCRIPTION FACTOR BINDING SITES. DURING THE 1-YEAR F99 PHASE, OTX2 BINDING ACTIVITY WILL BE PROFILED IN INTACT AND FGF2-TREATED RPE CELLS AT E4 AND E5 STAGES. ADDITIONALLY, SINGLE NUCLEI RNA-SEQUENCING WILL CAPTURE THE HETEROGENEOUS TRANSCRIPTIONAL STATES OF RPE CELLS DURING DIFFERENTIATION AND FGF2 TREATMENT RESPONSE AT E4 AND E5. THESE RESULTS WILL BE INTEGRATED TO INTO A MODEL THAT DESCRIBES HOW CHANGES IN THE RPE GENE REGULATORY LANDSCAPE CULMINATES IN A LOSS OF NEURAL COMPETENCY. IN SPECIFIC AIM 2, THE GENE REGULATORY NETWORKS PRESENT IN ADULT VERTEBRATE MODELS OF CENTRAL NERVOUS SYSTEM REGENERATION WILL BE INTERROGATED TO INSPIRE NOVEL ROUTES FOR THE INDUCTION OF MAMMALIAN REGENERATION. THIS K00 PHASE WILL FOCUS ON THE DEVELOPMENT OF KEY RESEARCH SKILLS, INCLUDING MULTI-OMICS DATA ANALYSIS APPROACHES, TECHNIQUES FOR SPATIAL TRANSCRIPTOMICS AND SINGLE CELL EPIGENOMICS, AND CROSS-SPECIES GENOMICS / TRANSCRIPTOMICS. UP TO 4 YEARS WILL BE SPENT ON THE K00 PHASE IN AN ENVIRONMENT DIRECTLY SUPPORTIVE OF THESE APPLICATIONS. SPECIFIC PROFESSIONAL DEVELOPMENT OBJECTIVES WILL BE CONCURRENTLY PURSUED, SUCH AS PEDAGOGICAL DEVELOPMENT, DIVERSITY OUTREACH INITIATIVES, AND GRANT WRITING. TOGETHER, THESE AIMS ENCOMPASS A CAREER DEVELOPMENT PLAN THAT WILL LEAD TO FORMATION OF AN INDEPENDENT RESEARCH PROGRAM AND RESULT IN IMPACTFUL RESEARCH FOCUSED ON EXPANDING HUMAN CENTRAL NERVOUS SYSTEM REGENERATIVE CAPACITY.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | ($33k) | 5/20/25 | ||
| Not listed | $0 | 12/13/24 | ||
| Not listed | $0 | 12/13/24 | ||
| Not listed | $81.2k | 6/17/24 | ||
| Not listed | $81.2k | 6/17/24 |